← Back to Clinical Trials
RecruitingNCT06689241
Rivaroxaban Versus Enoxaparin for Prophylaxis of Venous Thromboembolism in Bariatric Surgery
◆ AI Clinical Summary
Plain-language summary for patients
Trial Parameters
ConditionMorbid Obesity
SponsorAlexandria University
Study TypeINTERVENTIONAL
PhaseN/A
Enrollment162
SexALL
Min Age20 Years
Max Age60 Years
Start Date2024-10-01
Completion2025-12-01
All Conditions
Interventions
Enoxaparinrivaroxaban
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
Brief Summary
Rivaroxaban versus enoxaparin for prophylaxis of venous thromboembolism in morbidly obese patients undergoing bariatric surgery: An open\_label randomized controlled trial
Eligibility Criteria
Inclusion Criteria: * Age: 20-60 years, both sexes. * ASA physical status class I to III. * BMI 35-50 kg/m² Exclusion Criteria: * Severe cardiac disorder * chronic renal failure * liver cirrhosis * major psychological disorder
Related Trials
NCT06689241
Rivaroxaban Versus Enoxaparin for Prophylaxis of Venous Thromboembolism in Bariatric Surgery
View Trial →
NCT06413264
Ultrasonography Guided Pneumoperitoneum for Laparoscopic Surgery in Morbidly Obese Patients
View Trial →
NCT03517072
Determinants of the Long-Term Success of Bariatric Surgery
View Trial →